RxDoctor Payments Data

Farah Dawood, MD

Clinical Cardiac Electrophysiology · Chula Vista, CANPI 1922263466

Payments from drug & device makers

$23,910in general payments, 2019–2025

Across 560 payments — averaging $42.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$12K
  • Boston Scientific$3K
  • Abbott$2K
  • Edwards Lifesciences$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$825
  • Cvrx, Inc.$600
  • plus $5K from 41 others

What the payments were for

  • Speaking & faculty fees$4,25018%
  • Travel & lodging$5,18222%
  • Food & beverage$14,47861%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,910 in reported general payments places this provider in the 35th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$383,280
Medicare patients
546
Services billed
3,330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban231$264,240
EntrestoSacubitril/Valsartan84$111,509
XareltoRivaroxaban68$63,557
FarxigaDapagliflozin Propanediol25$22,222
JardianceEmpagliflozin20$20,170
MounjaroTirzepatide19$19,047
MultaqDronedarone Hcl13$17,255
OzempicSemaglutide13$13,866
BrilintaTicagrelor13$10,282
Flecainide Acetate185$5,180
Midodrine Hcl38$4,730
SotalolSotalol Hcl155$2,162
Amiodarone Hcl50$2,159
Losartan Potassium159$1,938
Metoprolol Succinate138$1,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$495$264,240231 claims
NovartisEntresto$331$111,50984 claims
Johnson & JohnsonXarelto$177$63,55768 claims
AstraZenecaFarxiga, Brilinta$127$32,50438 claims
Boehringer IngelheimJardiance$160$20,17020 claims
Lilly USA, LLCMounjaro$44$19,04719 claims
Sanofi-aventis U.S. LLCMultaq$70$17,25513 claims
Novo NordiskOzempic$145$13,86613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →